Immunitybio is trading at $8.19, up +6.09%, alongside a broad market rally after August CPI showed 3.4% annual inflation, matching forecasts and easing immediate concerns about upside surprises.
- No clear company-specific announcement directly explains the move.
- A newly published Anktiva patent application and upcoming lung-cancer conference may support investor interest; recent coverage linked prior weakness to those developments.
- Volume data unavailable.